FY2018 EPS Estimates for AstraZeneca plc Decreased by Analyst (AZN)
AstraZeneca plc (NYSE:AZN) – Analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Tuesday. Jefferies Group analyst J. Holford now anticipates that the company will earn $1.78 per share for the year, down from their previous estimate of $1.94. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.88 EPS, FY2020 earnings at $2.19 EPS, FY2021 earnings at $2.68 EPS and FY2022 earnings at $3.21 EPS.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.57 by $0.55. The company had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a return on equity of 34.02% and a net margin of 15.90%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.32 earnings per share.
AstraZeneca (AZN) traded up $0.09 on Wednesday, reaching $35.08. The company had a trading volume of 2,844,663 shares, compared to its average volume of 3,329,873. The stock has a market capitalization of $88,380.00, a price-to-earnings ratio of 25.06, a P/E/G ratio of 3.42 and a beta of 0.76. AstraZeneca has a 12 month low of $26.51 and a 12 month high of $35.92. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Fisher Asset Management LLC boosted its holdings in shares of AstraZeneca by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after purchasing an additional 519,717 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after purchasing an additional 310,389 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of AstraZeneca by 7.1% in the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock valued at $102,643,000 after purchasing an additional 199,519 shares during the period. Capital Bank & Trust Co boosted its holdings in shares of AstraZeneca by 2.1% in the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock valued at $92,499,000 after purchasing an additional 57,353 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of AstraZeneca by 18.3% in the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock valued at $86,695,000 after purchasing an additional 395,699 shares during the period. Hedge funds and other institutional investors own 14.75% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/17/fy2018-eps-estimates-for-astrazeneca-plc-decreased-by-analyst-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.